Recent developments include Q3 2026 earnings reporting a loss but revenue exceeding expectations, leadership changes with Simeon Kohl named CEO and Ben Albert becoming Chief Business Officer, and ongoing strategic initiatives.

• Health Catalyst reported a Q3 loss but revenue exceeded expectations, with detailed key metrics discussed in earnings coverage [N1][N2].
• In September 2026, Simeon Kohl was named CEO, with Ben Albert transitioning to Chief Business Officer [N4].
• The company held its Q2 2026 earnings call and provided highlights and key metrics in August 2026 [N5][N6][N7][N8].

Health Catalyst’s integrated healthcare analytics platform and professional services create value for healthcare providers by improving care coordination and population health management. The company’s restructuring initiatives and leadership changes aim to streamline operations and focus on high-conviction technology opportunities. The divestiture of the Vitalware Business may allow Health Catalyst to concentrate on core offerings. Its liquidity position and recent net income indicate operational stability. Continued innovation and effective client support could enhance client retention and attract new customers, supporting business resilience amid competitive pressures.

Health Catalyst operates in a highly competitive and rapidly evolving healthcare technology market with significant pressure from large, well-financed competitors. The company’s restructuring and platform migration efforts carry execution risks, including potential client dissatisfaction and revenue churn. The divestiture of the Vitalware Business reduces business scope and may negatively impact revenue and profitability. Macroeconomic challenges, including inflation, interest rates, and healthcare funding cuts, may reduce client spending and delay sales cycles. Operational disruptions from workforce reductions and strategic transitions could adversely affect performance and financial results.

Health Catalyst’s moat is based on its integrated healthcare data analytics platform combined with professional services and client support tailored to healthcare providers. The company’s ability to offer a comprehensive solution that addresses multiple aspects of healthcare data management and care coordination differentiates it from niche vendors and standalone products. Its established client relationships, ongoing restructuring to align resources with strategic priorities, and leadership with deep healthcare and technology experience contribute to its competitive positioning. However, the company faces significant competition from larger, well-resourced firms with broader offerings and established distribution networks, which challenges its market share and pricing power.

• Intense Competition: Health Catalyst faces competition from large healthcare IT firms with greater resources and established client relationships, which may limit market share and pricing flexibility.
• Industry Dynamics and Client Consolidation: Changes in healthcare industry structure, including client and vendor consolidation and shifts toward EHR companies’ analytics services, may reduce demand for Health Catalyst’s solutions.
• Macroeconomic and Market Risks: Economic challenges such as inflation, interest rates, funding cuts, and geopolitical conflicts may reduce healthcare spending, delay client decisions, and impact financial performance.
• Execution Risks from Restructuring and Platform Migration: Ongoing restructuring initiatives and migration to new platforms like Health Catalyst Ignite involve risks of operational disruption, client dissatisfaction, revenue churn, and increased costs.
• Divestiture Impact: The sale of the Vitalware Business reduces business diversification and may negatively affect revenue, profitability, and client relationships if transition is not managed effectively.

• Health Catalyst, Inc. is a publicly traded company on Nasdaq under ticker HCAT [S1].
• The company operates in the healthcare technology sector, providing data analytics, healthcare consulting, care management, population health management, and health information exchange solutions [S1,Q0-Q9].
• Health Catalyst faces competition from large, well-financed companies including Epic Systems, Oracle Health, Optum Analytics, IBM, and niche vendors offering stand-alone products [Q0-Q2].
• The company has undergone multiple workforce reductions and restructuring initiatives since 2023 to optimize cost structure and align resources with strategic priorities, including Project Nexus and the Vitalware Transaction [Q5-Q7].
• Health Catalyst divested its high-margin Vitalware Business, which reduces business scope and may impact revenue and profitability [Q7-Q8].
• The company’s sales cycle for new platform clients is typically about one year, with shorter cycles for point solution applications like Health Catalyst Ignite [Q8-Q9].
• The company’s professional services and client support are critical to client retention and sales, requiring specialized healthcare and technical expertise [Q8].
• As of September 30, 2026, Health Catalyst reported cash and cash equivalents of $53.7 million, short-term investments of $25.2 million, current assets of $133.0 million, current liabilities of $78.1 million, a current ratio of 1.7, and a cash ratio of 1.01 [S2].
• Net income for the quarter ending September 30, 2026, was $40.5 million with basic EPS of $0.54 and diluted EPS of $0.53 [S2].
• Benjamin Albert has served as CEO since February 2026, previously serving as President and COO; Simeon Kohl was named CEO in September 2026 with Ben Albert becoming Chief Business Officer [N4,S1].
• The board of directors includes experienced executives with backgrounds in healthcare, technology, finance, and governance [S1].
• The company faces risks from intense competition, evolving healthcare industry dynamics, macroeconomic challenges, and operational risks related to restructuring and platform migration [Q0-Q9].
• Recent news reports indicate Health Catalyst reported a Q3 loss but revenue exceeded expectations, with detailed key metrics discussed in earnings coverage [N1,N2].